Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches.
Crohn’s disease
combination therapy
dual targeted therapy
swap
switch
switch;
ulcerative colitis, ;
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
02
2021
accepted:
11
03
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.
Identifiants
pubmed: 33995579
doi: 10.1177/17562848211006669
pii: 10.1177_17562848211006669
pmc: PMC8082976
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17562848211006669Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare the following conflicts of interest: Giuseppe Privitera received consultancy fees from Alphasigma. Daniela Pugliese received speaker fees from AbbVie, MSD, Takeda, Janssen and Pfizer. Franco Scaldaferri: advisory board for Abbvie, Janssen, MSD, Sanofi and Takeda. Luisa Guidi: consultancies and/or speaker fees from: AbbVie, Janssen, MSD, Mundipharma, Takeda, Vifor Pharma and Zambon. Antonio Gasbarrini reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE, and Sanofi S.p.A, personal fees for acting as a speaker for Takeda S.p.A, AbbVie, and Sandoz S.p.A, and personal fees for acting on advisory boards for VSL3 and Eisai. Alessandro Armuzzi: consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Ferring, Gilead, Janssen, Lilly, MSD, Mylan, Pfizer, Samsung Bioepis, Sandoz and Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Biogen, Ferring, Giliead, Janssen, MSD, Mitsubishi-Tanabe, Nikkiso, Novartis, Pfizer, Sandoz, Samsung Bioepis and Takeda; and research grants from MSD, Pfizer and Takeda. All the other authors have no conflict of interest to declare.
Références
Nat Med. 2002 Oct;8(10):1089-97
pubmed: 12219085
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Clin Invest. 1994 Jul;94(1):449-53
pubmed: 8040288
J Crohns Colitis. 2018 Nov 28;12(12):1448-1458
pubmed: 30137280
Curr Opin Pharmacol. 2020 Dec;55:17-30
pubmed: 33039940
J Gastroenterol. 2010 Oct;45(10):999-1007
pubmed: 20405148
Aliment Pharmacol Ther. 2020 May;51(10):948-957
pubmed: 32249966
Clin Gastroenterol Hepatol. 2021 Apr;19(4):668-679.e8
pubmed: 32629124
J Crohns Colitis. 2020 Oct 5;14(10):1413-1423
pubmed: 32335670
J Immunol. 1999 Jul 1;163(1):143-7
pubmed: 10384110
Gut. 2019 Mar;68(3):423-433
pubmed: 29363534
Aliment Pharmacol Ther. 2020 May;51(9):831-842
pubmed: 32202328
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617
pubmed: 32068149
Cancer. 2020 Nov 15;126(22):4867-4877
pubmed: 32914866
Gastroenterology. 2020 Apr;158(5):1450-1461
pubmed: 31945371
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
J Clin Invest. 1990 Sep;86(3):972-80
pubmed: 2168444
F1000Res. 2020 Jan 28;9:
pubmed: 32047622
Paediatr Drugs. 2020 Aug;22(4):409-416
pubmed: 32378002
J Dig Dis. 2020 May;21(5):264-271
pubmed: 32324969
RMD Open. 2018 Apr 9;4(1):e000667
pubmed: 29657833
J Intern Med. 2017 Apr;281(4):365-382
pubmed: 28205262
Gastroenterology. 2014 Feb;146(2):392-400.e3
pubmed: 24512909
Cell. 2017 Dec 14;171(7):1678-1691.e13
pubmed: 29245013
Autoimmun Rev. 2014 Jan;13(1):24-30
pubmed: 23792214
Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038
pubmed: 32329532
Aliment Pharmacol Ther. 2020 Mar;51(6):637-643
pubmed: 31875986
J Crohns Colitis. 2018 May 25;12(6):635-643
pubmed: 29370397
Am J Gastroenterol. 2011 Apr;106(4):674-84
pubmed: 21407178
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):761-6
pubmed: 23446337
Inflamm Bowel Dis. 2019 Nov 14;25(12):1896-1905
pubmed: 30934053
United European Gastroenterol J. 2019 Jul;7(6):750-758
pubmed: 31316779
Clin Gastroenterol Hepatol. 2019 Feb;17(3):494-501
pubmed: 30213584
Aliment Pharmacol Ther. 2020 Aug;52(4):669-681
pubmed: 32656800
J Crohns Colitis. 2016 Nov;10(11):1259-1266
pubmed: 27566367
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27
pubmed: 21957906
Inflamm Bowel Dis. 2020 Nov 25;:
pubmed: 33236763
Aliment Pharmacol Ther. 2017 Jul;46(2):142-149
pubmed: 28449228
Am J Gastroenterol. 2016 May;111(5):748-9
pubmed: 27151127
Inflamm Bowel Dis. 2012 Jul;18(7):1260-6
pubmed: 21994045
Inflamm Bowel Dis. 2019 Jul 17;25(8):1417-1427
pubmed: 30839057
J Immunol. 1995 Mar 1;154(5):2434-40
pubmed: 7868909
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):702-710
pubmed: 32879465
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16711-6
pubmed: 21873195
Lancet. 2018 Dec 23;390(10114):2779-2789
pubmed: 29096949
Aliment Pharmacol Ther. 2020 Oct;52(8):1341-1352
pubmed: 32955122
Gut. 2014 Dec;63(12):1843-53
pubmed: 24970900
Rand Health Q. 2018 Mar 30;7(4):3
pubmed: 30083415
Aliment Pharmacol Ther. 2015 Oct;42(7):880-8
pubmed: 26235565
Gut. 2012 Feb;61(2):229-34
pubmed: 21948942
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Cytokine. 2012 Sep;59(3):451-9
pubmed: 22795953
Gut. 2020 Jul;69(7):1206-1212
pubmed: 31980448
Proc Natl Acad Sci U S A. 2019 Dec 16;:
pubmed: 31843928
Inflamm Bowel Dis. 2018 Aug 16;24(9):2078-2085
pubmed: 29718216
Inflamm Bowel Dis. 2020 Mar 4;26(4):606-616
pubmed: 31504569
Gastroenterology. 2008 Jun;134(7):1861-8
pubmed: 18440315
Inflamm Bowel Dis. 2018 Apr 23;24(5):997-1004
pubmed: 29668901
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Clin Gastroenterol Hepatol. 2020 Sep 16;:
pubmed: 32949730
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1426-1432.e1
pubmed: 27317850
Gut. 1997 Nov;41(5):651-7
pubmed: 9414973
Aliment Pharmacol Ther. 2015 Apr;41(7):613-23
pubmed: 25652884
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6
pubmed: 31945470
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Aliment Pharmacol Ther. 2018 Apr;47(8):1117-1125
pubmed: 29446098
Inflamm Bowel Dis. 2019 Oct 18;25(11):1805-1812
pubmed: 30931477
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1061-1070.e1
pubmed: 28238957
Inflamm Bowel Dis. 2020 Oct 30;:
pubmed: 33125058
Dig Liver Dis. 2019 Jul;51(7):972-977
pubmed: 30992173
Gut. 2019 May;68(5):814-828
pubmed: 29848778
Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355
pubmed: 29383030
Am J Gastroenterol. 2009 Mar;104(3):760-7
pubmed: 19174781
Aliment Pharmacol Ther. 2020 May;51(9):852-860
pubmed: 32201971
J Crohns Colitis. 2020 Jul 17;:
pubmed: 32674156
Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493
pubmed: 29751166
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053
pubmed: 29027257
Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31
pubmed: 21945953
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):8017-22
pubmed: 20385815
Inflamm Bowel Dis. 2018 Jan 18;24(2):394-401
pubmed: 29361087
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9362-E9370
pubmed: 30224451
Inflamm Bowel Dis. 2007 Jan;13(1):2-11
pubmed: 17206633
Dig Dis. 2020;38(6):466-473
pubmed: 32045927
J Crohns Colitis. 2020 May 21;14(4):542-556
pubmed: 31549158
Gastroenterology. 2021 Apr;160(5):1570-1583
pubmed: 33359090
Clin Transl Gastroenterol. 2020 Feb;11(2):e00128
pubmed: 32463619
J Gastroenterol Hepatol. 2019 Dec;34(12):2090-2095
pubmed: 31169926
Am J Gastroenterol. 2017 Jan;112(1):120-131
pubmed: 27958281
N Engl J Med. 2019 Sep 26;381(13):1215-1226
pubmed: 31553834
Clin Exp Immunol. 1997 Feb;107(2):353-8
pubmed: 9030875
Aliment Pharmacol Ther. 2020 Jul;52(1):123-134
pubmed: 32441396
Gut. 2014 Jun;63(6):919-27
pubmed: 23878167
Immunol Lett. 2010 Jan 18;128(1):80-5
pubmed: 19913053
PLoS One. 2013;8(1):e54562
pubmed: 23349929
J Clin Gastroenterol. 2021 Jan;55(1):e1-e7
pubmed: 32011403
Eur J Immunol. 2004 Sep;34(9):2347-55
pubmed: 15307167
Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2
pubmed: 25066837
Aliment Pharmacol Ther. 2017 Apr;45(8):1128-1134
pubmed: 28230306
Gut. 2007 Sep;56(9):1226-31
pubmed: 17229796
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508
Inflamm Bowel Dis. 2021 Apr 15;27(5):655-661
pubmed: 32676662
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):790-802
pubmed: 30353856
Clin Gastroenterol Hepatol. 2018 Sep;16(9):1374-1384
pubmed: 29481970
Am J Gastroenterol. 2020 Feb;115(2):179-189
pubmed: 31809296
Aliment Pharmacol Ther. 2018 Aug;48(4):394-409
pubmed: 29920733
J Immunol. 1999 Jun 1;162(11):6829-35
pubmed: 10352304
Digestion. 1994;55(6):368-73
pubmed: 7705549